selective activation p53-mediated tumour suppression high-grade tumours 
non-small cell lung carcinoma nsclc leading cause cancer-related death worldwide overall year survival rate % deregulation ras pathway frequent hallmark nsclc often mutations directly activate kras p53 also frequently inactivated nsclc oncogenic ras can potent trigger p53 ref seems likely oncogenic ras signalling major persistent role driving selection p53 hence pharmacological restoration p53 appealing therapeutic strategy treating disease model probable therapeutic impact p53 restoration spontaneously evolving mouse model nsclc initiated sporadic oncogenic activation endogenous kras surprisingly p53 restoration failed induce significant regression established tumours although result significant decrease relative proportion high-grade tumours due selective activation p53 aggressive tumour cells within tumour selective activation p53 correlates marked upregulation ras signal intensity induction oncogenic signalling sensor p19arf ref data indicate p53-mediated tumour suppression triggered oncogenic ras signal flux exceeds critical threshold importantly failure low-level oncogenic kras engage p53 reveals inherent limits capacity p53 restrain early tumour evolution efficacy therapeutic p53 restoration eradicate cancers 
